Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders

  • García-Gutiérrez, María Salud
  • Torregrosa, Abraham B.
  • Navarrete, Francisco
  • Navarro, Daniela
  • Manzanares, Jorge
Research carried out during the last 30 years since the first identification of CB2r in 1993 has changed the landscape of this receptor's role and therapeutic utility. Initially, studies focused on elucidating the role of CB2r at the periphery since it was first characterized in spleen and lymphocytes. Later, CB2r was found in the brain not only under pathological conditions but also under basal conditions. It is now known that this receptor is expressed in different brain regions and different cell types, including neurons and microglia. Experimental studies have provided robust evidence that CB2r is involved in the modulation of the immune system, neuroinflammation, oxidative stress and neuroprotection. Besides, CB2r mediated the response to stress, anxiety, and depression. Also, CB2r plays a relevant role in modulating the reinforcing properties of different drugs of abuse, including alcohol, nicotine and cocaine. In this review, we summarize the cumulative knowledge regarding the immunomodulatory, anti-inflammatory, antioxidant, and neuroprotective properties of CB2r against the development of neurodegenerative diseases. Indeed, we cover the anxiolytic and antidepressant potential of CB2r, which raises the therapeutic interest of this receptor in different psychiatric diseases associated with anxiety and depression. Finally, we discuss the involvement of CB2r in the regulation of drug addiction. A better understanding of the properties of CB2r is essential for the pharmacological development of this receptor in different neurodegenerative, psychiatric, and addictive disorders., This work was supported by the INSTITUTO DE SALUD CARLOS III, SPANISH MINISTRY OF SCIENCE AND INNOVATION, grant number PI18/00576 to MSGG and JM, and RED DE INVESTIGACIÓN EN ATENCIÓN PRIMARIA DE ADICCIONES, INSTITUTO DE SALUD CARLOS III, SPANISH MINISTRY OF SCIENCE AND INNOVATION, grant number RD21/0009/0008 to JM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Alterations of pro- and anti-inflammatory cytokines balance and superoxide dismutase in the dorsolateral prefrontal cortex of suicide decedents

  • García-Gutiérrez, María Salud
  • Caparrós, Esther
  • Torregrosa, Abraham B.
  • Martínez-López, Sebastián
  • Gasparyan, Ani
  • Giner, Salvador
  • Manzanares, Jorge
Recent studies have suggested that the immune system may be a key player in the pathophysiology of suicide. In this context, access to brain samples from individuals who died by suicide is of particular importance. Our study is designed to thoroughly investigate the link between suicide and brain immune system alterations. We analyzed changes in gene and protein expression of proinflammatory cytokines, IL-6 and TGF-β, and anti-inflammatory cytokine, IL-10, in the dorsolateral prefrontal cortex (DLPFC) of 33 suicide decedents (S) (with no clinical psychiatric history or treatment with anxiolytics or antidepressants) and 29 controls (C) using qPCR and ELISAs, respectively. Additionally, we evaluated superoxide dismutase 1 (SOD1) activity using ELISAs. S and C were matched for age and postmortem interval. Our results revealed an inverse correlation between pro- and anti-inflammatory cytokine levels in the DLPFC of S compared to C, with IL-6 and TGF-β increased and IL-10 reduced. Interestingly, contrasting changes were noted in gene expression across all analyzed targets, suggesting a potential homeostatic compensatory mechanism that warrants further analysis in large-scale studies. These alterations were accompanied by lower SOD1 activity in the DLPFC of S compared to C. These findings indicate an association between an inflammatory brain state and increased oxidative stress with suicide., This work was supported by the INSTITUTO DE SALUD CARLOS III, SPANISH MINISTRY OF SCIENCE AND INNOVATION, grant number PI18/00576 to MSGG and JM and RED DE INVESTIGACIÓN EN ATENCIÓN PRIMARIA DE ADICCIONES, INSTITUTO DE SALUD CARLOS III, SPANISH MINISTRY OF SCIENCE AND INNOVATION, grant number RD21/0009/0008 to JM. The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cannabidiol extending beyond neuroprotection toward neuronal repair: A potential regenerative modulator

  • García-Gutiérrez, María Salud
  • Manzanares, Jorge
Cannabidiol (CBD), the second most significant phytocannabinoid in the plant Cannabis sativa, which lacks potential as a drug of abuse (Viudez-Martinez et al., 2019), has gained widespread attention due to its anti-inflammatory, antioxidant, and antidepressant properties (Garcia-Gutierrez et al., 2020). Additionally, CBD exhibits neuroprotective properties, preserving neuronal viability and function by preventing or limiting cellular damage. Our team has demonstrated that CBD produces rapid antidepressant-like effects in a murine model of chronic mild stress, restoring hippocampal expression of brain-derived neurotrophic factor (BDNF), serotonin 1A (5-HT1A), and peroxisome proliferator-activated receptor delta (PPARδ), and surpassing the effects of the conventional selective serotonin reuptake inhibitor sertraline. Similarly, CBD promotes hippocampal neurogenesis and enhances synaptic plasticity (Garcia-Gutierrez et al., 2023). Besides, CBD restores hippocampal neurodegeneration in a mouse model of fetal alcohol spectrum disorder (Gasparyan et al., 2023)., This work was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, grant number PI18/00576 to MSGG and JMR and Red de Investigación en Atención Primaria de Adicciones, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, grant number RD21/0009/0008 and RD24/0003/0002, and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) to JM. The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed